Enlight Biosciences forms oral drug delivery company
Entrega will create oral formulations of biologic drugs normally requiring injection
Enlight Biosciences, a Boston, US-based firm established in partnership with a group of leading pharmaceutical companies, has formed a company called Entrega to develop oral drug delivery technologies for biologic drugs used to treat diabetes, cancer and inflammatory disease.
Entrega will initially create orally bioavailable formulations of several of the biologic drugs that are made by Enlight’s pharmaceutical partners and typically require injection.
Entrega will receive upfront and research milestone payments. The firm, whose scientific advisory board is chaired by entrepreneur and MIT professor Robert Langer, will remain independent and retain all rights to its platform technology.
Enlight Biosciences started in 2008 as a collaboration between Pfizer, Merck, Eli Lilly, and Boston-based PureTech Ventures. The firm has since forged partnerships with Johnson & Johnson, Novartis and Abbott Laboratories.
